(Q37951860)

25 August 2017

title

Recurrent ovarian cancer: when and how to treat (English)

1 reference

25 August 2017

1 reference

Marcia Hall

1

1 reference

25 August 2017

Gordon Rustin

series ordinal

2

1 reference

25 August 2017

publication date

1 December 2011

1 reference

25 August 2017

number of pages

13

1 reference

inferred from page(s)

published in

Current Oncology Reports

1 reference

25 August 2017

volume

13

1 reference

25 August 2017

issue

6

1 reference

25 August 2017

page(s)

459-471

1 reference

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: A retrospective Italian multicentric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Surveillance of patients after initial treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Effective palliative radiotherapy for symptomatic recurrent or residual ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Weekly paclitaxel in the treatment of recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Hypersensitivity reactions to antineoplastic agents: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Aromatase inhibitors in gynecologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Hormone replacement therapy and survival after surgery for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

No rules without exception: long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Antiangiogenic drugs in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Late congestive heart failure after hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Making the best of PARP inhibitors in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

What is the role of dose-dense therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gyna

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

The role of regular physical examination in the detection of ovarian cancer recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0199-3

Selective irradiation for the treatment of recurrent ovarian carcinoma involving the vagina or rectum

21 January 2018

1 reference

12 December 2020

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

12 December 2020

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels

1 reference

12 December 2020

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design

1 reference

12 December 2020

Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels

1 reference

12 December 2020

Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer

1 reference

12 December 2020

The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma

1 reference

12 December 2020

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels

1 reference

12 December 2020

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

1 reference

12 December 2020

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

12 December 2020

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

1 reference

12 December 2020

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125

1 reference

12 December 2020

Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma

1 reference

12 December 2020

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

1 reference

12 December 2020

Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis

1 reference

12 December 2020

Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).

1 reference

12 December 2020

PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer

1 reference

12 December 2020

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

1 reference

12 December 2020

Tamoxifen for relapse of ovarian cancer

1 reference

12 December 2020

Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial

1 reference

12 December 2020

Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses

1 reference

12 December 2020

Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma

1 reference

12 December 2020

Peritoneal metastases: detection with spiral CT in patients with ovarian cancer

1 reference

12 December 2020

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

1 reference

12 December 2020

Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation☆

1 reference

12 December 2020

Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer

1 reference

12 December 2020

Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer

1 reference

12 December 2020

The experience of long-term hospital follow-up for women who have suffered early stage gynecological cancer: a qualitative interview study

1 reference

12 December 2020

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

12 December 2020

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study

1 reference

12 December 2020

The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer

1 reference

12 December 2020

Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer

1 reference

12 December 2020

10.1007/S11912-011-0199-3

Identifiers

DOI

1 reference

25 August 2017

1 reference